Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript

Revance Therapeutics, Inc. (RVNC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 22,620 shares @ $0
Paid exercise price by delivering 11,215 shares @ $18.91, valued at $212.1k
08/15/2023 4 Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 19,346 shares @ $0
Paid exercise price by delivering 9,592 shares @ $18.91, valued at $181.4k
08/15/2023 4 Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 22,620 shares @ $0
Paid exercise price by delivering 8,901 shares @ $18.91, valued at $168.3k
08/15/2023 4 Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 122,143 shares @ $0
Paid exercise price by delivering 48,064 shares @ $18.91, valued at $908.9k
08/14/2023 8-K Other Events  Interactive Data
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update"
08/04/2023 4 Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 26,279 shares @ $22.5713, valued at $593.2k
08/03/2023 144 Form 144 - Report of proposed sale of securities:
07/05/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 769 shares @ $15.606, valued at $12k
Sold 1,701 shares @ $25.04, valued at $42.6k
07/05/2023 4 Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 1,000 shares @ $15.606, valued at $15.6k
07/05/2023 4 Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 1,000 shares @ $15.606, valued at $15.6k
Sold 26,279 shares @ $24.9375, valued at $655.3k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/05/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 2,701 shares @ $30.57, valued at $82.6k
Sold 500 shares @ $31, valued at $15.5k
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 4 Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 42,349 shares @ $0
Sold 21,401 shares @ $34.5469, valued at $739.3k
05/16/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 42,349 shares @ $0
Sold 21,401 shares @ $34.5469, valued at $739.3k
05/16/2023 4 Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 175,649 shares @ $0
Sold 70,447 shares @ $34.5469, valued at $2.4M
05/16/2023 4 Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 52,395 shares @ $0
Sold 21,015 shares @ $34.5469, valued at $726k
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update"
05/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2023 4 Gangolli Julian S (Director) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 3,534 shares @ $0
Granted 5,915 options to buy @ $33.61, valued at $198.8k
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy